Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS)
- Previous Close
8.08 - Open
8.08 - Bid 8.06 x --
- Ask 8.07 x --
- Day's Range
7.97 - 8.10 - 52 Week Range
6.52 - 11.48 - Volume
5,758,145 - Avg. Volume
8,839,135 - Market Cap (intraday)
6.709B - Beta (5Y Monthly) --
- PE Ratio (TTM)
32.24 - EPS (TTM)
0.25 - Earnings Date --
- Forward Dividend & Yield 0.13 (1.60%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
--
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it offers development and manufacturing services to the pharmaceutical, cosmetics, and nutritional industries. The company was founded in 2010 and is based in Linhai, China.
www.ausunpharm.comRecent News: 603229.SS
View MorePerformance Overview: 603229.SS
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603229.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603229.SS
View MoreValuation Measures
Market Cap
6.71B
Enterprise Value
5.89B
Trailing P/E
32.32
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.46
Price/Book (mrq)
2.83
Enterprise Value/Revenue
7.35
Enterprise Value/EBITDA
23.13
Financial Highlights
Profitability and Income Statement
Profit Margin
26.66%
Return on Assets (ttm)
4.21%
Return on Equity (ttm)
9.21%
Revenue (ttm)
801.01M
Net Income Avi to Common (ttm)
213.51M
Diluted EPS (ttm)
0.25
Balance Sheet and Cash Flow
Total Cash (mrq)
1.11B
Total Debt/Equity (mrq)
12.27%
Levered Free Cash Flow (ttm)
-27.62M